Atticus Wealth Management LLC lessened its stake in Merck & Co., Inc. (NYSE:MRK – Free Report) by 11.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,237 shares of the company’s stock after selling 561 shares during the period. Atticus Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $559,000 as of its most recent SEC filing.
Other institutional investors also recently bought and sold shares of the company. Vermillion & White Wealth Management Group LLC bought a new stake in Merck & Co., Inc. in the fourth quarter valued at approximately $27,000. Burkett Financial Services LLC purchased a new position in shares of Merck & Co., Inc. in the fourth quarter worth $28,000. Bare Financial Services Inc bought a new stake in Merck & Co., Inc. during the 4th quarter valued at $28,000. Rakuten Securities Inc. purchased a new stake in Merck & Co., Inc. during the 4th quarter valued at $30,000. Finally, RIA Advisory Group LLC purchased a new stake in Merck & Co., Inc. during the 4th quarter valued at $30,000. 76.07% of the stock is currently owned by hedge funds and other institutional investors.
Merck & Co., Inc. Stock Down 4.6 %
Shares of MRK stock traded down $6.02 during mid-day trading on Friday, reaching $123.80. 57,055,458 shares of the company’s stock traded hands, compared to its average volume of 8,215,418. The company’s 50-day moving average price is $129.32 and its 200-day moving average price is $124.27. The company has a market cap of $313.56 billion, a P/E ratio of 137.56, a P/E/G ratio of 2.51 and a beta of 0.39. The company has a quick ratio of 0.99, a current ratio of 1.25 and a debt-to-equity ratio of 0.77. Merck & Co., Inc. has a 12 month low of $99.14 and a 12 month high of $134.63.
Merck & Co., Inc. Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Monday, July 8th. Investors of record on Monday, June 17th will be paid a $0.77 dividend. The ex-dividend date of this dividend is Monday, June 17th. This represents a $3.08 annualized dividend and a dividend yield of 2.49%. Merck & Co., Inc.’s payout ratio is currently 342.22%.
Wall Street Analyst Weigh In
Several brokerages have recently commented on MRK. TheStreet downgraded shares of Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research note on Monday, March 4th. Wells Fargo & Company upped their price target on Merck & Co., Inc. from $130.00 to $135.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 27th. Societe Generale lowered Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 price objective on the stock. in a research report on Monday, March 11th. Truist Financial boosted their target price on Merck & Co., Inc. from $142.00 to $143.00 and gave the company a “buy” rating in a research note on Friday, April 26th. Finally, Argus raised Merck & Co., Inc. to a “strong-buy” rating in a research note on Wednesday, June 5th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $133.00.
Read Our Latest Stock Analysis on MRK
About Merck & Co., Inc.
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Read More
- Five stocks we like better than Merck & Co., Inc.
- Retail Stocks Investing, Explained
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Why Invest in 5G? How to Invest in 5G Stocks
- MarketBeat Week in Review – 6/24 – 6/28
- Golden Cross Stocks: Pattern, Examples and Charts
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.